Kennislacunes

What is the effectivity and safety of antimuscarinic treatment or mirabegron/vibegron in elderly patients with urine incontinence, compared to placebo or no treatment?

 

P: Elderly with urine incontinence

I1: Antimuscarinic treatment (i.e.darifenacine, fesoterodine, tolterodine, solifenacine, oxybutinine) with or without bladder training/pelvic floor training

I2: Beta3-agonist (i.e. Mirabegron/vibegron) with or without bladder training/pelvic floor training

C1: Placebo, no treatment with or without bladder training/pelvic floor training

C2: Placebo, no treatment or antimuscarinic treatment with or without bladder training/pelvic floor training

O: reduced urge urine incontinence episodes, quality of life, adverse events/complications (in particular cognitive decline)